Development of Proteasome Inhibitors as Therapeutic Drugs.
Development of Proteasome Inhibitors as Therapeutic Drugs.
复制标题
DOI：
10.4172/2155-9899.s5-005
复制
发表时间：
2012-03-15
期刊：
影响因子：
--
通讯作者：
Shanker A
中科院分区：
文献类型：
--
作者：
Pellom ST Jr;Shanker A
蛋白酶体是在所有真核细胞的细胞质和细胞核中发现的多单位酶复合物，并且负责通过蛋白水解降解不需要的或受损的细胞内蛋白质，蛋白水解是一种破坏肽键的化学反应。蛋白酶体抑制剂通过靶向肿瘤细胞中的蛋白酶体功能为癌症治疗提供了一种有前途的方法。描述硼替佐米在治疗多发性骨髓瘤和套细胞淋巴瘤中的成功，本文综述了目前正在开发的各种蛋白酶体抑制剂，作为抗癌的分子靶向药物。蛋白酶体抑制剂可单独使用或与其他常规癌症疗法组合使用，以通过各种机制使肿瘤细胞对细胞死亡敏感并改善治疗益处。
The proteasome is a multi-unit enzyme complex found in the cytoplasm and nucleus of all eukaryotic cells and is responsible for degradation of unneeded or damaged intracellular proteins by proteolysis, a chemical reaction that breaks peptide bonds. Proteasome inhibition presents a promising approach to cancer therapy by targeting the proteasome function in tumor cells. Delineating the success of bortezomib in the treatment of multiple myeloma and mantle cell lymphoma, this review explores various proteasome inhibitors, currently in development, as molecular targeting agents in the fight against cancer. Proteasome inhibitors can be used alone or in combination with other conventional cancer therapies to sensitize tumor cells to cell death by various mechanisms and improve therapeutic benefits.